Patient characteristics (n = 28)
| Characteristic . | n/N . | % . |
|---|---|---|
| Median age (range), y | 58 (26-78) | |
| Ratio of males to females | 1 | |
| ECOG performance status >1 | 15 | 53 |
| High lactate dehydrogenase serum level | 11 | 40 |
| High CSF protein concentration* | 11/22 | 50 |
| Involvement of deep areas | 12 | 43 |
| IELSG risk score | ||
| Low | 5 | 18 |
| Intermediate | 19 | 68 |
| High | 4 | 14 |
| Sites of disease | ||
| Brain parenchyma | 28 | 100 |
| Intraocular disease | 3 | 10 |
| Meningeal dissemination† | 0 | 0 |
| Previous lines of therapy | ||
| ≥2 | 8 | 29 |
| ASCT | 7 | 25 |
| WBRT | 6 | 21 |
| Both ASCT and WBRT | 4 | 14 |
| Refractory disease‡ | 19 | 68 |
| Characteristic . | n/N . | % . |
|---|---|---|
| Median age (range), y | 58 (26-78) | |
| Ratio of males to females | 1 | |
| ECOG performance status >1 | 15 | 53 |
| High lactate dehydrogenase serum level | 11 | 40 |
| High CSF protein concentration* | 11/22 | 50 |
| Involvement of deep areas | 12 | 43 |
| IELSG risk score | ||
| Low | 5 | 18 |
| Intermediate | 19 | 68 |
| High | 4 | 14 |
| Sites of disease | ||
| Brain parenchyma | 28 | 100 |
| Intraocular disease | 3 | 10 |
| Meningeal dissemination† | 0 | 0 |
| Previous lines of therapy | ||
| ≥2 | 8 | 29 |
| ASCT | 7 | 25 |
| WBRT | 6 | 21 |
| Both ASCT and WBRT | 4 | 14 |
| Refractory disease‡ | 19 | 68 |
ECOG, Eastern Cooperative Oncology Group.
Lumbar puncture was contraindicated in 6 patients; per protocol, CSF protein concentration was considered an unfavorable prognostic feature in IELSG risk score in these patients.
Meningeal/CSF involvement was not an exclusion criteria.
Refractory disease was defined by the progression of lymphoma within the 3 months since the completion of the last line of treatment before trial registration.